Amgen Warns Against Conflating Oncology And Inflammation Biosimilars
As Biosimilar Sales Track To $2bn
Amgen’s management took a deep dive into biosimilar market dynamics during the company’s third-quarter earnings call, as the California-based biotech continued to enjoy success for biosimilars in the US and Europe.
You may also be interested in...
Amgen management spoke at length about biosimilars during the company’s two-and-a-half-hour-long business review meeting, with the launch of its Amjevita (adalimumab-atto) biosimilar now less than a year away.
Amgen has once again touched on its impending expansion into US inflammation/immunology biosimilars, with launches for adalimumab and ustekinumab scheduled for the coming years.
Amgen has hit back at Sandoz’ petition for a writ of certiorari against a US Court of Appeals for the Federal Circuit decision that leaves the biosimilar sponsor unable to market its Enbrel biosimilar more than three decades after the biologic was first launched.